COVID-19 Update from BioSpectra, Inc.

In direct response to the announced COVID-19 pandemic, BioSpectra has developed a mitigation and business continuity plan.

 

Regarding mitigation, we have taken appropriate steps with our employees and facilities to keep our manufacturing plants operating at normal rates and virus-free in compliance with our cGMP operational standards. In addition, we have been working closely with our raw material suppliers in the US, Europe and Asia to monitor and react to any potential supply chain issues. To date, we have experienced zero significant interruptions in raw material supply, including those coming out of mainland China. Our Inventory Management program places our customers in a position to be unaffected by any of the international delays caused by this pandemic. We have even been able to secure emergency levels of additional material throughout the first quarter of 2020 where unplanned critical needs have developed. We have not experienced any reduction in our normal on-time-and-fill rate for orders to our contract customers. Currently we do not foresee any significant issues of concern in the near future.

 

Regarding business continuity, it is our intent to continue to operate in this way, and we are working hard to sustain that. We have redundant personnel for all critical functions. Currently, we are not experiencing any reduction in workforce beyond normal seasonal flu and cold rates.  If that should change, you will be notified of any potential impact this might have on the supply of any product from us. 

 

If you have any further questions or concerns, please feel free to contact me directly and I would be happy to respond to them immediately,

 

Stay Healthy and COVID-19 Free.

 

 

Sincerely,

Paul DiMarco | Vice President

Sales & Marketing

Office:  +1.610.599.3477

Mobile: +1.610.442.0341

Email:   This email address is being protected from spambots. You need JavaScript enabled to view it.